Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients

Ana Luisa Ordoñez-Vázquez, Eva Juárez-Hernández, Julia María Zuarth-Vázquez, Martha Helena Ramos-Ostos, Misael Uribe, Graciela Castro-Narro and Iván López-Méndez ()
Additional contact information
Ana Luisa Ordoñez-Vázquez: Gastroenterology and Obesity Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Eva Juárez-Hernández: Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Julia María Zuarth-Vázquez: Internal Medicine Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Martha Helena Ramos-Ostos: Diagnosis and Treatment Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Misael Uribe: Gastroenterology and Obesity Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Graciela Castro-Narro: Transplants and Hepatology Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Iván López-Méndez: Transplants and Hepatology Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico

IJERPH, 2022, vol. 19, issue 19, 1-10

Abstract: Background: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. Recently, the term metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed and adapted to body mass index (BMI). This study describes the impact on prevalence of the application of both criteria in overweight and lean patients. Methods: Patients who were evaluated for liver steatosis by transient elastography were included and divided according to BMI (≥25 kg/m 2 and <25 kg/m 2 ) and classified as NAFLD or MAFLD, according to metabolic abnormalities. Differences in prevalence were evaluated applying both criteria. A multivariate analysis was performed to evaluate independent associations of metabolic abnormalities and liver steatosis in lean patients. Results: 3847 patients were included. In overweight patients (61%), the prevalence NAFLD was 63.6% and 65.3% for MAFLD ( p = 0.22). In contrast, the prevalence of MAFLD was lower (7.9% vs. 18.3%, p ≤ 0.001) in lean patients. In this group, higher age, fasting glucose, triglycerides, and waist circumference showed independent association with liver steatosis. Conclusion: The application of NAFLD/MAFLD criteria did not show prevalence differences in overweight patients. With MAFLD criteria, the prevalence is lower in lean patients, but patients with high risk of progression of liver disease for steatosis were identified, according to their metabolic abnormalities.

Keywords: metabolic syndrome; body mass index; liver disease; NAFLD; MAFLD (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/19/12221/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/19/12221/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:19:p:12221-:d:926156

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().